<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />


<meta name="author" content="Study Team" />

<meta name="date" content="2025-04-28" />

<title>Hep C → AKI Safety Study: Causal Road-map &amp; Analysis Plan</title>

<script src="site_libs/header-attrs-2.29/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/bootstrap.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/highlightjs-9.12.0/default.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>









<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-default  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">HOME</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="RWE_tutorial.html">Introduction: TL Roadmap in RWE</a>
</li>
<li>
  <a href="case_study_AKI.html">Case study intro: Hep. C and AKI</a>
</li>
<li>
  <a href="roadmapV2.html">Case study Roadmap in RWE</a>
</li>
<li>
  <a href="PS_analysis.html">Propensity score matching analysis</a>
</li>
<li>
  <a href="TMLE_analysis.html">Targeted learning analysis</a>
</li>
<li>
  <a href="results_comparisons.html">Analysis comparisons</a>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">Hep C → AKI Safety Study: Causal Road-map
&amp; Analysis Plan</h1>
<h4 class="author">Study Team</h4>
<h4 class="date">2025-04-28</h4>

</div>


<div id="scientific-motivation-trial-emulation-context"
class="section level3">
<h3>0 Scientific motivation &amp; trial-emulation context</h3>
<ul>
<li><em>Drug-induced AKI is rare yet clinically serious</em>; only a
very large claims + EHR cohort can attain power.</li>
<li>Pre-specify an <strong>outcome-blind “sandbox”</strong>: all
modelling choices (covariate screening, learner library, weight
truncation, estimator) are tuned via resampling that <em>permutes
treatment labels</em> <strong>or</strong> <em>simulates outcomes under
known effects</em> before unblinding. :contentReference<span
index="0">oaicite:0</span></li>
</ul>
</div>
<div id="causal-question-estimands-causal-model" class="section level3">
<h3>1 Causal question, estimands &amp; causal model</h3>
<div id="a-primary-and-alternative-estimands-ich-e9-r1-attributes"
class="section level4">
<h4>1a Primary and alternative estimands (ICH E9 R1 attributes)</h4>
<p>Primary target (unchanged): <strong>90-day ITT risk difference (RD)
and risk ratio (RR)</strong>. <em>Refinements</em> - Add the
<strong>difference in restricted mean survival time (RMST)</strong> for
non-PH robustness. :contentReference<span index="1">oaicite:1</span> -
Document <em>versions</em> of SOF regimens (SOF±RBV, LDV/SOF, SOF/VEL,
SOF/VEL/VOX).</p>
</div>
<div id="b-expanded-dag" class="section level4">
<h4>1b Expanded DAG</h4>
<ul>
<li>Include <em>time-varying nephrotoxin exposure</em> and <em>drug
discontinuation</em> as potential mediators/confounders.</li>
<li>Per-protocol estimands will require longitudinal TMLE or
inverse-probability censoring weights.</li>
</ul>
</div>
</div>
<div id="observed-data-structure-rwd-quality" class="section level3">
<h3>2 Observed-data structure &amp; RWD quality</h3>
<ul>
<li><strong>Fit-for-purpose checklist</strong></li>
<li>Exposure → pharmacy claims</li>
<li>Baseline eGFR → EHR labs</li>
<li>AKI → validated ICD phenotype (+ chart sample)</li>
<li>Add SSA Death Master + EHR deaths to mitigate informative
censoring.</li>
</ul>
</div>
<div id="identifiability-diagnostics" class="section level3">
<h3>3 Identifiability diagnostics</h3>
<ul>
<li><strong>Positivity</strong>: inspect overlap with propensity-score
density plots; trim or apply outcome-adaptive lasso to restore
overlap.</li>
<li><strong>Exchangeability</strong>: employ a negative-control outcome
(ankle sprain) and negative-control exposure (PPIs).</li>
</ul>
</div>
<div id="statistical-estimand" class="section level3">
<h3>4 Statistical estimand</h3>
<p><span class="math display">\[ \psi_{\text{obs}} \;=\;
\mathbb{E}_{W}\!\bigl[\, P(\text{AKI}\le 90\text{ d}\mid A=1,W)\;-\;
P(\text{AKI}\le 90\text{ d}\mid A=0,W) \bigr]. \]</span></p>
</div>
<div id="estimation-plan" class="section level3">
<h3>5 Estimation plan</h3>
<ul>
<li><strong>TMLE + Super Learner</strong> library: logistic GLM,
xgboost, BART, outcome-adaptive lasso. - Stabilise weights; truncate at
<span class="math inline">\(\sqrt{n}\,\ln(n)/5\)</span>.<br />
</li>
<li>Use influence-function SEs → 95 % Wald CIs.</li>
</ul>
</div>
<div id="outcome-blind-simulations" class="section level3">
<h3>6 Outcome-blind simulations</h3>
<ul>
<li>Run ≥ 500 pseudo-trials with the empirical <span
class="math inline">\(P(W)\)</span> but true RD ∈ {0, −2, −5}/1000.</li>
<li>Compare bias, MSE and 95 % coverage for TMLE, IPTW, PS-matched Cox,
Fine-Gray; <strong>lock-in</strong> the top performer before
unblinding.</li>
</ul>
</div>
<div id="robustness-sensitivity" class="section level3">
<h3>7 Robustness &amp; sensitivity</h3>
<ul>
<li><strong>G-value</strong> = minimal causal gap (on RD scale) that
moves the 95 % CI to the null; report in RD-units, SE-units and
Adj-units.</li>
<li>Report <strong>E-values</strong> for unmeasured confounding
<em>alongside</em> the G-value.</li>
<li>Multiverse analysis: PS specification, weight truncation, outcome
definition.</li>
</ul>
</div>
<div id="table-1" class="section level3">
<h3>Table 1</h3>
<table style="width:100%;">
<colgroup>
<col width="1%" />
<col width="17%" />
<col width="10%" />
<col width="36%" />
<col width="30%" />
<col width="4%" />
</colgroup>
<thead>
<tr class="header">
<th>Menu of candidate estimands</th>
<th>#</th>
<th>Label</th>
<th>Measure</th>
<th>Population &amp; intercurrent-event strategy</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>1</strong></td>
<td><strong>Primary ITT</strong></td>
<td>ΔRisk, RR</td>
<td>All initiators; ignore switching (treatment-policy)</td>
<td>Effect of <em>offering</em> SOF regimen</td>
<td>Regulatory default</td>
</tr>
<tr class="even">
<td>2</td>
<td>ITT RMST diff</td>
<td>RMST_0-90</td>
<td>Same as 1</td>
<td>Average delay in AKI</td>
<td>Non-PH robust</td>
</tr>
<tr class="odd">
<td>3</td>
<td>Per-protocol</td>
<td>ΔRisk on-tx</td>
<td>Censor 30 d after switch</td>
<td>Effect of <em>continuous exposure</em></td>
<td>Needs IPCW</td>
</tr>
<tr class="even">
<td>4</td>
<td>Cause-specific HR</td>
<td>Cox HR</td>
<td>Censor at switch/death</td>
<td>Instantaneous hazard ratio</td>
<td>HR caveats</td>
</tr>
<tr class="odd">
<td>5</td>
<td>Sub-distribution HR</td>
<td>Fine-Gray SHR</td>
<td>Treat death as competing risk</td>
<td>Effect on cumulative incidence</td>
<td></td>
</tr>
<tr class="even">
<td>6</td>
<td>Principal stratum</td>
<td>RD in adherers</td>
<td>Restrict to “would adhere ≥ 8 wk” stratum</td>
<td>Biological efficacy</td>
<td>Strong assumptions</td>
</tr>
<tr class="odd">
<td>7</td>
<td>CKD subgroup</td>
<td>RD | CKD</td>
<td>eGFR &lt; 60 at baseline</td>
<td>Effect in CKD population</td>
<td>Lower power</td>
</tr>
<tr class="even">
<td>8</td>
<td>Guideline g-formula</td>
<td>ΔRisk under rule</td>
<td>Dynamic rule: “start SOF if eGFR &gt; 30”</td>
<td>Effect of guideline policy</td>
<td>Needs longitudinal TMLE</td>
</tr>
</tbody>
</table>
<table>
<colgroup>
<col width="10%" />
<col width="29%" />
<col width="31%" />
<col width="29%" />
</colgroup>
<thead>
<tr class="header">
<th>Strategy</th>
<th>Core idea &amp; target quantity</th>
<th>Scientific question answered</th>
<th>Typical analytical choices</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Treatment-policy</strong> (“intention-to-treat–like”)</td>
<td>The outcome is taken <strong>as observed</strong>, regardless of any
post-randomization (intercurrent) events. The target parameter is the
effect had <em>everyone been assigned</em> the experimental vs. control
regimen, with no restrictions on what happens thereafter.</td>
<td><em>“What is the effect of starting treatment X compared with Y in
real-world clinical use, where dose changes, rescue meds and adherence
issues occur?”</em></td>
<td>Analyse all randomized patients from time 0 to the planned end of
follow-up; do <strong>not</strong> censor at intercurrent events. For
T2E endpoints this often implies Kaplan–Meier/Cox with administrative
censoring only (but beware that the hazard ratio may then mix direct and
indirect pathway effects).</td>
</tr>
<tr class="even">
<td><strong>Hypothetical</strong></td>
<td>Imagine a world in which a specific intercurrent event <strong>would
not occur</strong>. The estimand contrasts the counterfactual outcomes
under treatment vs. control <em>if</em> everyone were prevented from
experiencing that event.</td>
<td><em>“What would the treatment effect be if no patient discontinued
because of intolerance?”</em></td>
<td>Requires modelling or imputation: e.g. (i) censor at the
intercurrent event <em>and</em> assume independent censoring (→ standard
survival methods) or (ii) impute post-event outcomes via multiple
imputation / g-formula / joint modelling. The key is to articulate (and
justify) the assumptions used to emulate the hypothetical world.</td>
</tr>
<tr class="odd">
<td><strong>While-on-treatment</strong></td>
<td>Focus on outcomes <strong>up to</strong> the intercurrent event
(treatment discontinuation, switch, etc.). The estimand is the treatment
effect <em>while patients remain on their originally assigned
therapy</em>.</td>
<td><em>“What is the effect of treatment X compared with Y, up to the
point a patient stops or switches?”</em></td>
<td>Right-censor at the intercurrent event; then estimate
survival/objective up to that time. Valid inference needs a “no
unmeasured prognostic reason for stopping” assumption (independent
censoring given covariates). The resulting quantity is sometimes called
the <em>per-protocol</em> or <em>on-treatment</em> effect.</td>
</tr>
<tr class="even">
<td><strong>Principal-stratum</strong></td>
<td>Restrict comparison to the latent subgroup of patients who
<strong>would not experience</strong> the intercurrent event <em>under
either treatment</em>. The estimand is the causal effect within that
principal stratum.</td>
<td><em>“Among patients who would adhere fully irrespective of
assignment, what is the treatment effect?”</em></td>
<td>Requires methods from causal inference (e.g. instrumental-variable
approaches, g-estimation, Bayesian mixture models) to identify the
unobservable stratum. Generally complex and assumption-dependent; rarely
the primary estimand in regulatory trials but useful for
sensitivity/supportive analysis.</td>
</tr>
</tbody>
</table>
<table>
<colgroup>
<col width="1%" />
<col width="8%" />
<col width="17%" />
<col width="21%" />
<col width="14%" />
<col width="11%" />
<col width="25%" />
</colgroup>
<thead>
<tr class="header">
<th>#</th>
<th>Label / Estimand</th>
<th>Measure (target statistical quantity)</th>
<th>Population &amp; strategy for intercurrent events</th>
<th>Interpretation of the estimand</th>
<th>Notes / typical analysis</th>
<th>Causal question for the HepC–AKI study (SOF vs non-SOF)</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1</td>
<td><strong>Primary ITT</strong> (treatment-policy)</td>
<td>ΔRisk or Risk Ratio over 0-90 d</td>
<td>All initiators; ignore switching, discontinuation or death during
the 90 d window</td>
<td>Effect of <em>offering</em> a SOF-containing regimen versus a
non-SOF regimen on 90-day cumulative AKI risk</td>
<td>Regulatory default; implement with Kaplan–Meier risk difference /
ratio or TMLE for risk</td>
<td><em>“Among all HCV patients who start any DAA, how would the 90-day
risk of AKI differ if every patient were assigned a SOF regimen versus
if every patient were assigned a non-SOF regimen?”</em>
:contentReference<span index="0">oaicite:0</span>​:contentReference<span
index="1">oaicite:1</span></td>
</tr>
<tr class="even">
<td>2</td>
<td><strong>ITT RMST difference</strong></td>
<td>Difference in Restricted Mean Survival Time (RMST) for event-free
days 0-90</td>
<td>Same population &amp; strategy as #1</td>
<td>Average delay (or acceleration) of AKI within 90 d</td>
<td>Robust to non-proportional hazards; estimate via RMST package or
TMLE for RMST</td>
<td><em>“What is the average increase (or decrease) in AKI-free days
during the first 90 days if all initiators received SOF versus
non-SOF?”</em></td>
</tr>
<tr class="odd">
<td>3</td>
<td><strong>Per-protocol</strong> (while-on-treatment)</td>
<td>ΔRisk while on-treatment; censor 30 d after switch/stop</td>
<td>Patients followed until 30 d after discontinuation or switch; censor
thereafter</td>
<td>Effect of <em>continuous exposure</em> to SOF vs non-SOF</td>
<td>Needs inverse-probability of censoring weights (IPCW) or
longitudinal TMLE</td>
<td><em>“Among patients who would remain on their initial DAA for ≥30
days, what would be the difference in AKI risk had they stayed on SOF
the whole time versus stayed on non-SOF?”</em></td>
</tr>
<tr class="even">
<td>4</td>
<td><strong>Cause-specific HR</strong></td>
<td>Cox cause-specific Hazard Ratio</td>
<td>Censor at treatment switch and at death; competing events treated as
censoring</td>
<td>Instantaneous hazard among still-at-risk individuals</td>
<td>HR depends on proportional-hazard assumption; interpret with caution
:contentReference<span index="2">oaicite:2</span>​:contentReference<span
index="3">oaicite:3</span></td>
<td><em>“At any given day among patients still alive, what is the
instantaneous rate of AKI if they were on SOF compared with if they were
on non-SOF, assuming they have not switched regimens?”</em></td>
</tr>
<tr class="odd">
<td>5</td>
<td><strong>Sub-distribution HR</strong> (Fine–Gray)</td>
<td>Sub-distribution Hazard Ratio</td>
<td>Treat death as a competing risk, keep treatment switching as
censoring</td>
<td>Effect of treatment on cumulative incidence function of AKI
accounting for competing death</td>
<td>Useful when death precludes AKI and is common</td>
<td><em>“How does initiating SOF (vs non-SOF) change the cumulative
incidence of AKI over follow-up when deaths are treated as competing
events?”</em></td>
</tr>
<tr class="even">
<td>6</td>
<td><strong>Principal-stratum</strong></td>
<td>Risk Difference among latent adherers (≥8 wk)</td>
<td>Restrict to patients who <em>would</em> adhere ≥8 weeks under either
regimen</td>
<td>Biological efficacy in always-adherers</td>
<td>Requires strong, unverifiable assumptions or IV/g-estimation</td>
<td><em>“Among HCV patients who would adhere to ≥8 weeks of therapy
regardless of which DAA they start, what is the difference in AKI risk
if they took SOF versus non-SOF?”</em></td>
</tr>
<tr class="odd">
<td>7</td>
<td><strong>CKD subgroup estimand</strong></td>
<td>Risk Difference in eGFR &lt; 60 subgroup</td>
<td>Population limited to baseline CKD; treatment-policy for
intercurrent events</td>
<td>Effect in patients with chronic kidney disease</td>
<td>Lower power; prespecified subgroup</td>
<td><em>“Within the subgroup of HCV patients with baseline eGFR &lt; 60
mL/min/1.73 m², how would the risk of AKI change if all received SOF
rather than non-SOF?”</em></td>
</tr>
<tr class="even">
<td>8</td>
<td><strong>Guideline g-formula rule</strong> (dynamic regimen)</td>
<td>ΔRisk under a dynamic treatment rule</td>
<td>Rule: “start SOF only if baseline eGFR &gt; 30”; censor
deviations</td>
<td>Effect of guideline-based policy compared with universal
non-SOF</td>
<td>Needs longitudinal TMLE / parametric g-formula</td>
<td><em>“What would be the population 90-day AKI risk if clinicians
followed the rule <em>‘prescribe SOF only when eGFR &gt; 30’</em> versus
prescribing non-SOF to everyone?”</em></td>
</tr>
</tbody>
</table>
<table style="width:100%;">
<colgroup>
<col width="1%" />
<col width="8%" />
<col width="18%" />
<col width="22%" />
<col width="15%" />
<col width="12%" />
<col width="19%" />
</colgroup>
<thead>
<tr class="header">
<th>#</th>
<th>Label / Estimand</th>
<th>Measure (target statistical quantity)</th>
<th>Population &amp; strategy for intercurrent events</th>
<th>Interpretation of the estimand</th>
<th>Notes / typical analysis</th>
<th><strong>Causal Roadmap &amp; TL considerations</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1</td>
<td><strong>Primary ITT</strong> (treatment-policy)</td>
<td>ΔRisk or Risk Ratio 0-90 d</td>
<td>All initiators; ignore switching, death</td>
<td>Effect of <em>offering</em> SOF regimen</td>
<td>Kaplan–Meier or TMLE for risk</td>
<td>• Roadmap Step 0: confirm the clinical question really is pragmatic.
• Prefer risk/RMST over Cox HR (HR non-causal). • Use TMLE + SL to
adjust for baseline covariates and minimise model miss-specification. •
Document assumptions (positivity, no un-measured confounding) and report
a non-parametric sensitivity curve to show how large a “causal gap”
would overturn inference. :contentReference<span
index="1">oaicite:1</span></td>
</tr>
<tr class="even">
<td>2</td>
<td><strong>ITT RMST difference</strong></td>
<td>Δ RMST<sub>0-90</sub></td>
<td>Same as #1</td>
<td>Mean delay/acceleration of AKI</td>
<td>RMST plug-in or TMLE for RMST</td>
<td>• RMST is a causal <em>contrast in the survival scale</em> endorsed
by Chen 2023 as more interpretable than HR. • Same
estimation/sensitivity principles as row 1, plus check administrative
censoring assumptions. :contentReference<span
index="2">oaicite:2</span>​:contentReference<span
index="3">oaicite:3</span></td>
</tr>
<tr class="odd">
<td>3</td>
<td><strong>Per-protocol</strong> (while-on-treatment)</td>
<td>ΔRisk while on-tx (censor 30 d post-switch)</td>
<td>Follow until 30 d after switch/stop</td>
<td>Effect of <em>continuous exposure</em></td>
<td>IPCW / longitudinal TMLE</td>
<td>• Roadmap Step 1: encode time-varying data structure. • Identify
longitudinal confounders of adherence and outcome; estimate dynamic
weights or fit sequential-TMLE. • Positivity often fragile → report
diagnostics &amp; truncate weights as in Williamson 2023.
:contentReference<span index="4">oaicite:4</span>​:contentReference<span
index="5">oaicite:5</span></td>
</tr>
<tr class="even">
<td>4</td>
<td><strong>Cause-specific HR</strong></td>
<td>Cox HR</td>
<td>Censor at switch/death</td>
<td>Instantaneous hazard among survivors</td>
<td>Standard Cox ± IPCW</td>
<td>• Roadmap warns HR rarely equals causal effect. • If kept, accompany
with causal parameter such as risk difference and justify PH assumption;
otherwise replace with TMLE-based risk or RMST. • Show how HR estimate
shifts when g-computation or TMLE is applied. :contentReference<span
index="6">oaicite:6</span></td>
</tr>
<tr class="odd">
<td>5</td>
<td><strong>Sub-distribution HR</strong> (Fine-Gray)</td>
<td>SHR</td>
<td>Death as competing risk</td>
<td>Effect on cumulative incidence</td>
<td>Fine-Gray / Aalen-Johansen</td>
<td>• Prefer direct estimation of CIF difference with TMLE instead of
SHR (non-collapsible). • Explicitly include competing death as
intercurrent event per Roadmap Step 0. • Sensitivity: vary
death-as-competing vs composite.</td>
</tr>
<tr class="even">
<td>6</td>
<td><strong>Principal-stratum</strong></td>
<td>RD in latent adherers (≥8 wk)</td>
<td>Restrict to “always-adherers”</td>
<td>Biological efficacy</td>
<td>IV / mixture models</td>
<td>• Roadmap Step 3 highlights lack of identifiability. • State
unverifiable assumptions; implement Bayesian or IV-based bounds; present
a bias-robust interval (causal gap plot).</td>
</tr>
<tr class="odd">
<td>7</td>
<td><strong>CKD subgroup</strong></td>
<td>RD in eGFR &lt; 60</td>
<td>Sub-pop of CKD; tx-policy for events</td>
<td>Effect in CKD patients</td>
<td>Stratified TMLE; lower power</td>
<td>• Roadmap: prespecify subgroup, avoid post-hoc fishing. • Ensure
positivity within subgroup; otherwise use pooled-targeted estimation
with interaction term and report shrinkage-based CI (Gruber 2024 Sect
4). :contentReference<span
index="7">oaicite:7</span>​:contentReference<span
index="8">oaicite:8</span></td>
</tr>
<tr class="even">
<td>8</td>
<td><strong>Guideline g-formula rule</strong></td>
<td>ΔRisk under dynamic rule</td>
<td>“Start SOF if eGFR &gt; 30”; censor deviations</td>
<td>Effect of guideline policy</td>
<td>Parametric g-formula / longitudinal TMLE</td>
<td>• Roadmap Step 2: define intervention as explicit stochastic policy.
• Check support along rule‐defined paths (positivity). • Estimate with
iterative TMLE; present policy-based risk curve and Monte-Carlo CI;
perform causal-gap sensitivity to violations of sequential
exchangeability. :contentReference<span
index="9">oaicite:9</span>​:contentReference<span
index="10">oaicite:10</span></td>
</tr>
</tbody>
</table>
<div id="legend-of-new-column" class="section level4">
<h4>Legend of new column</h4>
<p>Roadmap Step 0–6 refer to the ordered tasks in the Causal Roadmap
(formulate question, specify causal/statistical models, identify,
estimate with TL, and conduct sensitivity analysis). TMLE + SL =
Targeted-Minimum-Loss Estimation with Super-Learner ensemble; delivers
double-robust, efficiency-optimal estimates recommended by Chen 2023 and
Gruber 2024. “Causal gap” denotes the residual bias that would remain if
any identifying assumption fails; Roadmap Step 5 advocates reporting how
large a gap would flip the study’s conclusion.</p>
</div>
</div>
<div id="key-take-aways" class="section level3">
<h3>Key take-aways</h3>
<ol style="list-style-type: decimal">
<li>Outcome-blind simulations + collaborative learner choice →
objective, regulator-friendly tuning.</li>
<li>Diagnose &amp; treat positivity before estimation.</li>
<li>Prefer RD/RMST when non-PH is likely.</li>
<li>G-value offers transparent, scale-matched sensitivity
reporting.</li>
<li>Align TL workflow with ICH E9 (R1) for full auditability. ###
Session info</li>
</ol>
</div>




</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
